Facing Copaxone rivals, Teva looks to buy

Teva Pharmaceutical Industries ($TEVA) has some ambitious growth goals for 2015. And the way its multiple sclerosis drug Copaxone is growing, those ambitions appear more reasonable. But as Bloomberg points out, Copaxone faces new and forthcoming rivals, both branded and generic. It can't lean on that drug if it wants to deliver four years from now.

As a solution, Teva could rely on acquisitions more than it anticipated. Previously, the Israeli company had said that one-third of its growth to 2010 would come via dealmaking, with the rest being organic expansion. Now, Teva has cash on hand and access to lots more. It faces many of the same challenges that Big Pharma does.

So, as CFO Eyal Desheh tells the news service, the company is eyeing deals large and small--even as large or larger as its $4.9 billion buyout of Ratiopharm last year. "Are we ready for another acquisition the order of magnitude of Ratiopharm? The answer is yes," Desheh said. "We are looking at a number of targets."

- get more from Bloomberg
- see the interview, also from Bloomberg

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.